Abcam

Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays, and other kits. The company was founded by David Douglas Cleevely, Anthony Kouzarides, and Jonathan Simon Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.

CAMBRIDGE, England and WALTHAM, Mass. , May 17, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM), ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today notes that its founder and former director Dr. Jonathan Milner has indicated he will take steps to call an extraordinary general meeting ("EGM") of the Company's shareholders to elect himself to the Company's Board of Directors as Executive Chairman.

Abcam PLC: Statement on potential Extraordinary General Meeting

CAMBRIDGE, England and WALTHAM, Mass , May 17, 2023 /PRNewswire/ --  Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces the voting results from the Annual General Meeting (the "AGM") held today.  A total of 196,862,506 shares representing 85.7% of Abcam's issued and outstanding voting capital (including withheld) were voted in connection with the meeting.

ABCAM PLC Result of Annual General Meeting

Jonathan Milner Announces T hat He is Taking Steps to Call a n Extraordinary General Meeting of Abcam Shareholders

Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders

CAMBRIDGE, England and WALTHAM, Mass. , May 4, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following updates.

Abcam, plc Business Update

CAMBRIDGE, England and WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, notes the Form 13D filed today by founder and former director Dr Jonathan Milner and related press reports.

ABCAM PLC Comments on Investor Engagement

CAMBRIDGE, England and WALTHAM, Mass. , April 17, 2023 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the following investor events.

ABCAM PLC: Upcoming Abcam Investor Events

LAUSANNE, Switzerland & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)-- #spatialbiology--Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore's COMET™ platform.

Lunaphore and Abcam Announce Agreement for Primary Antibody Validation for Use on COMET™, Combining Power of Trusted Antibody Provider With Superior Multiplex Capabilities

CAMBRIDGE, England and WALTHAM, Mass. , March 30, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities and Exchange Commission, the Abcam plc Annual Report and Accounts 2022 (the "Annual Report") have been published today and are available on the Abcam plc website at  corporate.abcam.com The Annual Report will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications.

Abcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting

State Bank of India ADR (NASDAQ:ABCM ) Q4 2022 Earnings Conference Call March 20, 2023 8:00 AM ET Company Participants Tommy Thomas - Vice President of Investor Relations Alan Hirzel - Chief Executive Officer Michael Baldock - Chief Financial Officer Conference Call Participants Tejas Sevant - Morgan Stanley Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - Bank of America Charles Weston - RBC Justin Bowers - Deutsche Bank Operator Hello, and welcome to the Abcam plc Full-Year 2022 Earnings Conference Call. My name is Alex, I'll be coordinating the call today.

Abcam plc (ABCM) Q4 2022 Earnings Call Transcript

15% Reported Revenue Growth & 8% Constant Exchange Rate Revenue Growth: Demand for Abcam In-house Products Continues CAMBRIDGE, England and WALTHAM, Mass.  , March 20, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its results for the year ended 31 December 2022 (the 'period').

ABCAM PLC: Final results for the year ended 31 December 2022

CAMBRIDGE, England and WALTHAM, Mass. , March 10, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m.

Abcam to Report Full Year Results on Monday, March 20, 2023

CAMBRIDGE, England and WALTHAM, Mass. , Dec. 12, 2022 /PRNewswire/ -- Abcam plc, (AIM: ABC) and (NASDAQ: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, today provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the "AIM Delisting"), as originally announced on 17 October 2022.

Abcam plc: Update on AIM Delisting

Abcam PLC ( ABCM , Financial) is a $3.8 billion market cap biotechnology stock on the Nasdaq Global Select Market. It is moving its primary listing from London's AIM (previously known as the Alternative Investment Market) and will cancel its AIM shares on 13 December 2022 following shareholder approval given last week.

Is Abcam the Perfect Nasdaq Stock?

CAMBRIDGE, England and WALTHAM, Mass. , Nov. 11, 2022 /PRNewswire/ -- Abcam plc (AIM: ABCM) (ABC: ABCM) (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, today announces that the resolution put to its General Meeting held today for the cancellation of the admission of its Ordinary Shares to trading on AIM was passed.

ABCAM PLC: Result of General Meeting - Shareholders approve AIM Delisting

NanoString Technologies

SEATTLE & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString's high-plex spatial multiomic so

NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

Proposed Cancellation of Admission of Ordinary Shares to Trading on AIM and Notice of General Meeting Notice of General Meeting to be held on 11 November 2022    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

ABCAM PLC: Proposed resolution for cancellation of AIM listing

I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company.

Abcam: A Good Growth Stock In The Healthcare Market

20% constant exchange rate revenue growth in H1: Demand for Abcam In-house Products Increases CAMBRIDGE, England and WALTHAM, Mass. , Sept. 12, 2022 /PRNewswire/ -- Abcam plc (NASDAQ: ABCM) (AIM: ABC) ('Abcam', the 'Group' or the 'Company'), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2022 (the 'period').

ABCAM PLC: Interim results for the six-month period ended 30 June 2022

CAMBRIDGE, England , July 20, 2022 /PRNewswire/ -- Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022.  The Company will release its full results for the six-month period on 12 September 2022.

ABCAM PLC First Half Trading Update

CAMBRIDGE, England , June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools.

Abcam: Appointment of Vice President of Investor Relations

CAMBRIDGE, England, March 25, 2022 /PRNewswire/ --  Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.

Abcam the most awarded company at 2022 industry awards

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Abcam PLC Sponsored ADR (ABCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 27% Upside in Abcam PLC Sponsored ADR (ABCM): Here's What You Should Know

Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript

Growing demand for Abcam's portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

Twist Bioscience Corp

CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and

News for Abcam Stock (ABCM)